Home

äranägemisel Harva vähk nmd pharma rahvuslipp piir Ernest Shackleton

NMD Pharma begins first clinical trial: "Our entire team can be enormously  proud"
NMD Pharma begins first clinical trial: "Our entire team can be enormously proud"

UNIVERSITY OF COPENHAGEN Project title Novel Treatments of Neuromuscular  Disease Mentor 1 Pontus Gourdon, MSc & PhD,
UNIVERSITY OF COPENHAGEN Project title Novel Treatments of Neuromuscular Disease Mentor 1 Pontus Gourdon, MSc & PhD,

NMD Pharma - Capnova
NMD Pharma - Capnova

NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance  Treatments of Neuromuscular Disorders
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

NMD Pharma Information | NMD Pharma Profile
NMD Pharma Information | NMD Pharma Profile

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

NMD Pharma
NMD Pharma

NMD Pharma | The Lundbeck Foundation
NMD Pharma | The Lundbeck Foundation

NMD Pharma
NMD Pharma

Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

Seneste nyheder om NMD Pharma - finans.dk
Seneste nyheder om NMD Pharma - finans.dk

NMD Pharma breder sig til nye områder før næste kapitalrejsning
NMD Pharma breder sig til nye områder før næste kapitalrejsning

Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle  Neuromuscular Transmission Disorders #BioEquity2016… "
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "

NMD Pharma
NMD Pharma

NMD Pharma
NMD Pharma

NMD Pharma
NMD Pharma

ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing

Thomas Pedersen - BioLeader Interview - PIR International
Thomas Pedersen - BioLeader Interview - PIR International

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

Thomas K. Petersen - COO at NMD Pharma | The Org
Thomas K. Petersen - COO at NMD Pharma | The Org

Nmd Pharma A/S, Aarhus N | firma | krak.dk
Nmd Pharma A/S, Aarhus N | firma | krak.dk

Monique Schiersing - Director at NMD Pharma | The Org
Monique Schiersing - Director at NMD Pharma | The Org

NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma
NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma